Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository

BACKGROUND: Cardiac glycosides such as digoxin, digitoxin and ouabain are still used around the world to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) and/or atrial fibrillation (AF). However, in the US, only digoxin is licensed for treating these illnesses, and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Banaag, Amanda L., Pollard, Harvey B., Koehlmoos, Tracey P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024520/
https://www.ncbi.nlm.nih.gov/pubmed/36933173
http://dx.doi.org/10.1007/s40801-023-00360-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024520/
https://www.ncbi.nlm.nih.gov/pubmed/36933173
http://dx.doi.org/10.1007/s40801-023-00360-8

Ejemplares similares